Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and tolerability study of faricimab in Chinese participants previously enrolled in Roche faricimab studies
ISRCTN14123846Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of faricimab in age-related macular degeneration (AMD), sponsored by Roche. Primary endpoints: Ocular safety assessments, Post-treatment ocular effect assessments and 1 more. Started Jul 2021; status: completed.
02
Drugs
faricimab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on ISRCTN14123846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14123846.